Biocon Biologics

Biologics represent the cutting-edge of biomedical research, and biosimilars present an enormous opportunity to provide affordable access to these advanced therapies. Biosimilars are intended to increase patients’ access to biologics as they are priced lower than branded, novel biologics and may further lead to the competitive pricing of the original biologic.

Biosimilars can ensure a greater and more equitable access to biologic therapies and to healthcare generally. Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide.